Eckert & Ziegler SE (FRA:EUZ)

Germany · Delayed Price · Currency is EUR

12.01

-0.06 (-0.50%)

At close: Sep 18, 2026

Market Cap	758.43M -31.3%
Revenue (ttm)	312.50M +4.4%
Net Income	49.74M +35.7%
EPS	0.79 +36.4%
Shares Out	n/a
PE Ratio	15.25
Forward PE	14.53
Dividend	0.22 (1.83%)
Ex-Dividend Date	Jun 25, 2026

Volume	400
Open	12.10
Previous Close	12.07
Day's Range	12.01 - 12.10
52-Week Range	12.01 - 18.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu... [Read more]

Industry Industrial Inorganic Chemicals

Founded 1992

Employees 1,105

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol EUZ

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.

Financial Statements

News

Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ...

Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license i...

5 weeks ago - Finanz Nachrichten

Eckert & Ziegler SE Earnings Call Transcript: Q2 2026

First half 2026 saw stable revenues and 5% net income growth, with strong performance in medical and radiopharmaceuticals. Full-year guidance is maintained, expecting a stronger H2 driven by license payments and improved product mix. Cash remains strong and the company is nearly debt-free.

5 weeks ago - Transcripts

Eckert & Ziegler SE Quarterly report: Q2 2026

Eckert & Ziegler SE has published its Q2 2026 quarterly earnings report on August 13, 2026.

5 weeks ago - Filings

Eckert & Ziegler SE Slides: Q2 2026

Eckert & Ziegler SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.

5 weeks ago - Filings

EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...

5 weeks ago - Wallstreet:Online

EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

2 months ago - Wallstreet:Online

Eckert & Ziegler SE Slides: FY 2026

Eckert & Ziegler SE has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 26, 2026.

2 months ago - Filings

Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY

Original-Research: Eckert & Ziegler SE - from NuWays AG 13.05.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible ...

4 months ago - Finanz Nachrichten

Eckert & Ziegler SE Earnings Call Transcript: Q1 2026

Q1 2026 saw 7% sales growth and strong medical segment performance, offsetting a slow start in the IP segment. Full-year guidance is reaffirmed, with robust cash reserves and a focus on organic growth and targeted M&A. Competitive and market conditions remain stable.

4 months ago - Transcripts

Eckert & Ziegler SE Quarterly report: Q1 2026

Eckert & Ziegler SE has published its Q1 2026 quarterly earnings report on May 12, 2026.

4 months ago - Filings

Eckert & Ziegler SE Slides: Q1 2026

Eckert & Ziegler SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.

4 months ago - Filings

EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

5 months ago - Wallstreet:Online

Eckert & Ziegler SE Earnings Call Transcript: Q4 2025

Sales exceeded €300 million in 2025, driven by medical segment growth and global expansion, with EBIT margin at 25% and strong cash flow. 2026 guidance targets €320 million sales and €80 million EBIT adjusted, with continued CapEx and cautious outlook on license income and FX impacts.

5 months ago - Transcripts

Eckert & Ziegler SE Annual report: Q4 2025

Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.

5 months ago - Filings

Eckert & Ziegler SE Slides: Q4 2025

Eckert & Ziegler SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.

5 months ago - Filings

Eckert & Ziegler SE Annual report: Q4 2025

Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.

5 months ago - Filings

EQS-DD: Eckert & Ziegler SE: Dr. Gunnar Mann, Allocation of 12,545 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic ...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:17 CET/CEST The issuer is solely responsi...